



Article scientifique

Editorial

2016

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

---

## Standardizing end points in perioperative trials: towards a core and extended outcome set

---

Myles, P.S.; Grocott, M.P.W.; Boney, O; Moonesinghe, S.R.

Collaborators: Haller, Guy Serge Antoine

### How to cite

MYLES, P.S. et al. Standardizing end points in perioperative trials: towards a core and extended outcome set. In: British journal of anaesthesia, 2016, vol. 116, n° 5, p. 586–589. doi: 10.1093/bja/aew066

This publication URL: <https://archive-ouverte.unige.ch/unige:158519>

Publication DOI: [10.1093/bja/aew066](https://doi.org/10.1093/bja/aew066)

4. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. *Ann Intern Med* 2011; **154**: 523–8
5. Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. *Anesthesiology* 2014; **120**: 564–78
6. Wasowicz M, Syed S, Wijesundera DN, et al. Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study. *Br J Anaesth* 2016; **116**: 493–500
7. Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angiography. *J Am Coll Cardiol* 2007; **50**: 933–9
8. Ino Y, Kubo T, Tanaka A, et al. Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. *JACC Cardiovasc Interv* 2011; **4**: 76–82
9. Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. *N Engl J Med* 2014; **370**: 1494–503
10. Kamel H, Johnston SC, Kirkham JC, et al. Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction. *Circulation* 2012; **126**: 207–12
11. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *Circulation* 2014; **130**: 2215–45
12. Collaborators C-T, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 2010; **376**: 23–32
13. Roberts I, Perel P, Prieto-Merino D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. *BMJ* 2012; **345**: e5839
14. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. *J Am Coll Cardiol* 2000; **35**: 1288–94
15. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. *Lancet* 2008; **371**: 1839–47
16. Devereaux PJ, Sessler DI, Leslie K, et al. Clonidine in patients undergoing noncardiac surgery. *N Engl J Med* 2014; **370**: 1504–13
17. Myles PS, Leslie K, Chan MT, et al. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. *Lancet* 2014; **384**: 1446–54

*British Journal of Anaesthesia* **116** (5): 586–9 (2016)  
doi:10.1093/bja/aew066

## Standardizing end points in perioperative trials: towards a core and extended outcome set

P. S. Myles<sup>1,\*</sup>, M. P. W. Grocott<sup>2,3,4,5</sup>, O. Boney<sup>2,5</sup> and S. R. Moonesinghe<sup>2,5</sup>, on behalf of the COMPAC-StEP Group

<sup>1</sup> Department of Anaesthesia and Perioperative Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia,

<sup>2</sup> Health Services Research Centre, National Institute of Academic Anaesthesia, Royal College of Anaesthetists, London, UK,

<sup>3</sup> Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK,

<sup>4</sup> Critical Care Research Area, Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK, and

<sup>5</sup> Surgical Outcomes Research Centre, University College Hospital, London, UK

\*Corresponding author. E-mail: p.myles@alfred.org.au

Varied definitions and inconsistent reporting of outcomes across trials investigating similar clinical problems limit the value of this research.<sup>1–2</sup> Such variability also undermines systematic reviews and meta-analyses aiming to synthesize relevant primary research on a particular question.<sup>3,4</sup> Two key issues underpin this problem, namely which outcomes are selected and what criteria are used to define them. For example, even an apparently simple

and binary outcome, such as postoperative mortality, may be reported at different time points (commonly in hospital, 28, 30, or 90 days) and using alternative criteria (e.g. ‘all-cause mortality’ or ‘cardiovascular mortality’) in different trials. Likewise, inconsistent definitions of organ injury or composite end points (e.g. morbidity or quality-of-life measures) threaten the validity of any pooled analyses.<sup>5</sup> The findings of medical research should

**Table 1** Current Standardized Endpoints for Perioperative Medicine (StEP) working groups. MET, medical emergency team; MACE, major adverse cardiac events; IABP, intra-aortic balloon pump; POMS, post-operative morbidity score

Working groups	Proposed end points
Patient comfort Chair: Paul Myles	(i) Postoperative nausea and vomiting (ii) Perioperative pain measurement (iii) Quality of recovery scales (iv) Sleep quality/disturbance (v) Perioperative anxiety/stress (vi) Return of bowel function/ileus
Clinical indicators Chair: Guy Haller	(i) Perioperative hypothermia (ii) Perioperative iatrogenic injury (nerve injury, postoperative visual loss, pressure sores, dental damage, post-dural puncture headache) (iii) MET/rapid response calls; cardiorespiratory arrest; unplanned intensive care unit admission (iv) Unplanned hospital readmission; discharge destination
Cognition and stroke Chair: Lis Evered	(i) Stroke/transient ischaemic attack (including severity) (ii) Postoperative delirium/confusion (iii) Postoperative cognitive decline
Cardiovascular Chair: Scott Beattie and P. J. Devereaux	(i) Composite MACE (e.g. cardiovascular death, myocardial infarction, heart failure) (ii) Myocardial injury after non-cardiac surgery (utility of biomarkers) (iii) Arrhythmias (duration/severity/treatment needed) (iv) Venous thromboembolism (v) Hypotension/requirement for circulatory support (e.g. vasoactive drugs, IABP)
Respiratory Chair: Rupert Pearse	(i) Pulmonary complications: how defined and classified; consequences
Sepsis Chair: Mervyn Singer	(i) Wound infection (surgical site infection) (ii) Bloodstream infection
Renal Chair: David McIlroy	(i) Acute kidney injury (ii) Other renal outcomes
Bleeding and transfusion Chair: Duminda Wijeyesundara	(i) Blood loss (ii) Transfusion requirements
Organ failure and survival Chair: Michael Grocott	(i) Mortality measures (cause/time point) (ii) Composite morbidity scales (e.g. POMS/Clavien-Dindo)
Cancer and long-term survival Chair: Dan Sessler	(i) Long-term survival (ii) Disease recurrence (local/distant)
Patient-centred outcomes Chair: Ramani Moonesinghe	(i) Patient satisfaction (ii) Health-related quality of life (iii) Disability-free survival (iv) Return to work/normal functioning (v) Functional status/mobility/6 min walk test, other (vi) Home days (days alive and out of hospital)
Healthcare resource utilization Chair: Rob Sneyd	(i) Length of stay (intensive care unit/hospital) (ii) Health-care costs (iii) Fitness for discharge; delayed discharge

be replicated before they are considered 'true',<sup>2</sup> and clear and consistent measurement criteria are a prerequisite for replication. There is thus a pressing need to standardize end points in perioperative clinical trials and to agree on a core data set that is common to all trials.

Recent efforts to identify outcome measures for anaesthesia and intensive care studies have been helpful,<sup>6–8</sup> but these were not in accord with current guidelines<sup>9</sup> and did not consider the psychometric properties (validity, reliability, utility, and responsiveness) of the proposed outcome measures;<sup>10–11</sup> further work has been recommended.<sup>6–12</sup> Some measurement scales used in the perioperative setting have not undergone sufficient

psychometric validation<sup>13</sup> or have not determined the minimal clinically important difference needed to define a meaningful response to treatment.<sup>13–14</sup> Some candidate end points have existing generic or critical care definitions, or both, that may not be applicable in the perioperative ward or post-discharge setting. Furthermore, the relevance of outcome measures to important stakeholders, including patients, carers, health-care providers and policymakers, may not have been taken into account when designing studies. Other specialties have made good progress in standardizing end points for clinical trials; these specialties include cardiology,<sup>15</sup> respiratory medicine,<sup>16</sup> breast cancer,<sup>17</sup> and stroke.<sup>18</sup>

In June of 2015, the BJA sponsored a meeting of experienced perioperative triallists to establish a consensus process of standardizing end points in perioperative medicine. This 'Standardized Endpoints for Perioperative Medicine' (StEP) Group is currently working to provide expert, consensus-based<sup>19</sup> guidelines for clinical outcomes used in perioperative research. This process will feed into a parallel initiative with the aim of identifying a core outcome set (COS) for perioperative studies, the Core Outcomes Measures in Perioperative and Anaesthetic Care (COMPAC) initiative. Together, these two processes seek to standardize both the criteria for and selection of measures for perioperative researchers in order to harmonize outcome reporting and thereby enable the comparison, contrasting, and combination of results from diverse studies. Both the StEP and COMPAC guidelines will be produced according to established standards,<sup>9 20–25</sup> including formation of an expert group to define the scope, methods, and outputs and to oversee all stages of the process. For the StEP process, this will begin with a systematic review of end points, their definitions, and timing of assessment used in large published perioperative studies. The time course of recovery from surgery will be considered when determining the optimal time(s) of assessment. The published performance characteristics of any proposed instruments (i.e. validity, reliability, and responsiveness) will be evaluated and reported. Particular scrutiny will be given to composite end points according to the balance between the burden of data collection and the frequency and coherence of each component of the end point.<sup>5</sup> The StEP group will then make preliminary recommendations and aim to achieve consensus across a broader group of investigators and journal contributors. The final StEP guidelines will be published in one or more anaesthetic journals to maximize their dissemination to target audiences.<sup>19 26</sup> Whereas development of the StEP guidelines is a technical exercise driven in large part by expert interpretation of a complex scientific literature (top-down approach), the COMPAC initiative uses similar methods to achieve consensus between patients, carers, and a broad range of carers as to what are the most important outcome domains to include in a COS (bottom-up approach). Key outcomes from each StEP group will be mapped onto the domains identified by the COMPAC process (e.g. pain/discomfort, quality of life) in order to define a COS for perioperative studies.<sup>27</sup> The COMPAC-StEP methodology is based on an approach that has been successfully used by the Core Outcome Measures in Effectiveness Trials (COMET) initiative over a number of years.<sup>28</sup>

The StEP working groups have been identified (see Table 1). Each group consists of a chair and four to eight members who represent a breadth of relevant expertise in clinical trials and systematic reviews, and where relevant, health services research, biostatistics, psychometrics, and health economics. Where possible, members of each group have been drawn from at least four countries and at least two continents to provide diversity and global representation. Each StEP working group will be asked to identify one or two core outcome measures related to their area of interest that will be candidates for the COS, based on the domains of outcome identified through the COMPAC process. The resulting shortlist of proposed end points and their definitions will then be subjected to a two-stage Delphi process across all the StEP working groups and their clinical research collaborators, plus patient representatives, journal editors, and other relevant stakeholder representatives. We hope to present the final COMPAC-StEP Recommendations for Standardized Endpoints in Perioperative Trials at a workshop during the World Congress of Anaesthesiologists in Hong Kong in September

2016. The completed guidelines will also be published in the anaesthetic literature.

Consensus and consistency in the use of appropriate outcome measures in perioperative clinical trials, and their timing of assessments, should enhance the interpretation and translation of such research endeavours. Standardizing end points will also improve the validity of pooled analysis of clinical trials and assist those wanting to replicate trial results. These latter steps are necessary components of evidence-based practice. Comparison between studies is made easier, and other investigators will have a stronger foundation on which to design future, definitive trials. This will improve the value and efficiency of research.<sup>1 2</sup>

## Declaration of interest

P.S.M. is an editor of the *British Journal of Anaesthesia*; M.P.W.G. is an elected council member of the Royal College of Anaesthetists and the Director of the National Institute for Academic Anaesthesia's (NIAA) Health Services Research Centre (to end of March 2016). S.R.M. is the deputy director of the NIAA Health Services Research Centre and will be Director of the NIAA Health Services Research Centre (April 2016).

## References

1. Koroshetz W. A core set of trial outcomes for every medical discipline? *Br Med J* 2015; **350**: h85
2. Ioannidis JP. How to make more published research true. *PLoS Med* 2014; **11**: e1001747
3. Tovey D. The impact of Cochrane Reviews. *Cochrane Database Syst Rev* 2010; doi:10.1002/14651858.ED000007
4. Williamson P, Clarke M. The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: its role in improving Cochrane Reviews. *Cochrane Database Syst Rev* 2012; **5**: ED000041
5. Myles PS, Devereaux PJ. Pros and cons of composite end-points in anesthesia trials. *Anesthesiology* 2010; **113**: 776–8
6. Jammer I, Wickboldt N, Sander M, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. *Eur J Anaesthesiol* 2015; **32**: 88–105
7. Stundner O, Ortmaier R, Memtsoudis SG. Which outcomes related to regional anesthesia are most important for orthopedic surgery patients? *Anesthesiol Clin* 2014; **32**: 809–21
8. Bruce J, Russell EM, Mollison J, et al. The measurement and monitoring of surgical adverse events. *Health Technol Assess* 2001; **5**: 1–194
9. Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting guidelines. *PLoS Med* 2010; **7**: e1000217
10. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. *Qual Life Res* 2007; **16**: 717–23
11. Cohen ME, Marino RJ. The tools of disability outcomes research functional status measures. *Arch Phys Med Rehabil* 2000; **81**(12 Suppl 2): S21–9
12. Grocott MP. Standardisation of perioperative outcome measures. *Eur J Anaesthesiol* 2015; **32**: 83–4
13. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol* 2007; **60**: 34–42

14. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. *Mayo Clin Proc* 2002; **77**: 371–83
15. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *Circulation* 2015; **132**: 302–61
16. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 2009; **180**: 59–99
17. Fumagalli D, Bedard PL, Nahleh Z, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. *Lancet Oncol* 2012; **13**: e240–8
18. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. *Stroke* 2000; **31**: 1429–38
19. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. *Health Technol Assess* 1998; **2**: 1–88
20. Boukredid R, Abdoul H, Loustau M, et al. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. *PLoS ONE* 2011; **6**: e20476
21. Wang X, Chen Y, Yang N, et al. Methodology and reporting quality of reporting guidelines: systematic review. *BMC Med Res Methodol* 2015; **15**: 74
22. National Institute for Health and Care Excellence (NICE), 2014. Developing NICE guidelines: the manual. Available from [www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview](http://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview)
23. American College of Cardiology Foundation / American Heart Association (ACCF/AHA), 2010. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. Available from [http://my.americanheart.org/professional/StatementsGuidelines/PoliciesDevelopment/Development/Methodologies-and-Policies-from-the-ACCAHA-Task-Force-on-Practice-Guidelines\\_UCM\\_320470\\_Article.jsp](http://my.americanheart.org/professional/StatementsGuidelines/PoliciesDevelopment/Development/Methodologies-and-Policies-from-the-ACCAHA-Task-Force-on-Practice-Guidelines_UCM_320470_Article.jsp)
24. Bellera CA, Pulido M, Gourgou S, et al. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. *Eur J Cancer* 2013; **49**: 769–81
25. Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). *Ann Oncol* 2015; **26**: 873–9
26. Haller MC, van der Veer SN, Nagler EV, et al. A survey on the methodological processes and policies of renal guideline groups as a first step to harmonize renal guidelines. *Nephrol Dial Transplant* 2015; **30**: 1066–74
27. Boney O, Moonesinghe SR, Myles PS, et al. Standardizing endpoints in perioperative research. *Can J Anaesth* 2016; **63**: 159–68
28. Prinsen CA, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a 'core outcome set'. *Trials* 2014; **15**: 247

## Appendix

The COMPAC-StEP Executive consists of Paul Myles (Australia, Co-Chair) and Michael Grocott (UK, Co-Chair), and Bruce Bickard (South Africa), Oliver Boney (PhD Fellow, UK), Matthew Chan (Hong Kong), Lee Fleisher (USA), Cor Kalkman (The Netherlands), Andrea Kurz (USA), Ramani Moonesinghe (UK), and Duminda Wijeyesundera (Canada).

COMPAC-StEP Group members include: J. Bartoszko, W. S. Beattie, R. Bellomo, D. Buggy, L. Cabrini, J. Canet, T. Cook, D. J. Cooper, T. Corcoran, P. J. Devereaux, R. Eckenhoff, L. Evered, T. J. Gan, T. Gin, H. Grocott, G. Haller, S. Howell, M. Jayarajah, C. Kalkman, K. Karkouti, B. Kavanagh, A. Klein, G. Landoni, K. Leslie, D. R. McIlroy, D. Mazer, A. Moller, M. Mythen, M. Neuman, M. Neuman, R. Pearse, P. Peyton, J. Prowle, T. Richards, D. A. Scott, D. Sessler, A. Shaw, T. Short, M. Shulman, B. Silbert, M. Singer, J. R. Sneyd, D. Story, D. van Dijk, and W. van Klei.